Oct 16th 2012 - Edison Investment Research today published a report on GW Pharmaceuticals (GWP.L, LSE:GWP, LON:GWP) entitled "MOVE-ing The Dial". In summary, the report says:
Results of a ‘real-world’ study and an independent economic analysis confirm that Sativex is an efficacious and cost-effective therapy for MS spasticity. We see potential for GW Pharma’s licensing partners (Almirall, Bayer, Novartis) to use these data in their ongoing pricing/reimbursement discussions and marketing efforts. Moreover, the study findings provide greater confidence in our peak sales forecast for Sativex in MS spasticity of £64m.
Edison Investment Research is a leading international investment research company. It has won industry recognition, with awards both in the UK and internationally. The team of 95 includes over 60 analysts supported by a department of supervisory analysts, editors and assistants. Edison writes on more than 400 companies across every sector and works directly with corporates, fund managers, investment banks, brokers and other advisers. Edison’s research is read by institutional investors, alternative funds and wealth managers in more than 100 countries. Edison, founded in 2003, has offices in London, New York and Sydney and is authorised and regulated by the Financial Services Authority (www.fsa.gov.uk/register/firmBasicDetails.do?sid=181584). more »